Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects

被引:183
|
作者
Halbreich, U
Kinon, BJ
Gilmore, JA
Kahn, LS
机构
[1] SUNY Buffalo, Sch Med & Biomed Sci, Biobehav Program, Buffalo, NY 14214 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
hyperprolactinemia; schizophrenia; prolactin; antipsychotics; osteoporosis;
D O I
10.1016/S0306-4530(02)00112-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The neurologic processes involved in schizophrenia are complex and diverse and the mechanisms through which antipsychotic agents exert their effects have been only partly elucidated. Hyperprolactinemia is a common side effect of treatment with many antipsychotics and is particularly associated with conventional ('typical') agents as well as the atypical antipsychotic risperidone. In contrast, other atypical agents introduced over the last decade do not elevate prolactin levels. This article discusses the regulatory mechanisms involved in prolactin secretion, the physiologic role of prolactin, and the etiology of hyperprolactinemia. Elevated prolactin levels may play important roles, both direct and indirect, in various pathologic states, including breast cancer, osteoporosis, cardiovascular disorders, and sexual disturbances. Antipsychotic-induced hyperprolactinemia may be associated with similar clinical manifestations; these are examined with particular reference to patients with schizophrenia. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:53 / 67
页数:15
相关论文
共 50 条
  • [22] Immunomodulating Effects Depend on Prolactin Levels in Patients with Hyperprolactinemia
    Ewerman, Lea
    Landberg, Eva
    Hellberg, Sandra
    Hovland, Mina
    Sundin, Anna
    Jenmalm, Maria C.
    Ekman, Bertil
    Ernerudh, Jan
    Wahlberg, Jeanette
    HORMONE AND METABOLIC RESEARCH, 2020, 52 (04) : 228 - 235
  • [23] Prolactin levels in drug-naive patients with schizophrenia and other psychotic disorders
    Petrikis, Petros
    Tigas, Stelios
    Tzallas, Alexandros T.
    Archimandriti, Dimitra T.
    Skapinakis, Petros
    Mavreas, Venetsanos
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2016, 20 (03) : 165 - 169
  • [24] Relationship Between Plasma Levels of Prolactin and the Severity of Negative Symptoms in Patients with Schizophrenia
    Ates, Mehmet Alpay
    Tutuncu, Recep
    Oner, Ibrahim
    Ercan, Sarper
    Basoglu, Cengiz
    Algul, Ayhan
    Balibey, Hakan
    Ipcioglu, Osman Metin
    Cetin, Mesut
    Ebrinc, Servet
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 25 (01): : 27 - 37
  • [25] The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients
    Ohta, Chikako
    Yasui-Furukori, Norio
    Furukori, Hanako
    Tsuchimine, Shoko
    Saito, Manabu
    Nakagami, Taku
    Yoshizawa, Kaori
    Kaneko, Sunao
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (02) : 573 - 576
  • [26] Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
    Culpepper, Larry
    Vieta, Eduard
    Kelly, Deanna L.
    Patel, Mehul D.
    Szatmari, Balazs
    Hankinson, Arlene
    Earley, Willie R.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 995 - 1011
  • [27] Elevated levels of serum prolactin in patients with advanced multiple myeloma
    Gadó, K
    Rimanóczi, E
    Hasitz, A
    Gigler, G
    Tóth, BE
    Nagy, GM
    Pálóczi, K
    Domján, G
    NEUROIMMUNOMODULATION, 2001, 9 (04) : 231 - 236
  • [28] Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels
    Krysiak, Robert
    Okopien, Boguslaw
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 116 (03) : 251 - 256
  • [29] Sexual dysfunction factors in patients with schizophrenia treated with second generation antipsychotics: not only prolactin
    Martin, Joaquin C.
    Acuna, Maria J.
    Labrador, Jose
    Blanco, Matilde
    Casas, Cristina
    ACTAS ESPANOLAS DE PSIQUIATRIA, 2018, 46 (06): : 217 - 225
  • [30] Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review
    De Hert, M.
    Peuskens, J.
    Sabbe, T.
    Mitchell, A. J.
    Stubbs, B.
    Neven, P.
    Wildiers, H.
    Detraux, J.
    ACTA PSYCHIATRICA SCANDINAVICA, 2016, 133 (01) : 5 - 22